ClinicalTrials.gg
TerminatedNCT01641926Updated Aug 27, 2018Results posted

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

A Phase 3 interventional study of PEG-Intron™ and PEGASYS™ in Hepatitis B, Chronic, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-27.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
This study was terminated early due to poor recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic — 5 open to participants now, 5 under way, none of them phase 3. peginterferon alfa-2b · Hepatitis B, Chronic.

Enrollment
4th of 15
402 · median 254
Started
2012
with 1 other
Phase 3
5 of 15
none open now
Registered
5th of 15
by date
Lead sponsor
3 of 15
Merck Sharp & Dohme LLC

Among the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, this one is the 4th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 5th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

5 of the 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing peginterferon alfa-2b in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been treated with interferon.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Must be able to adhere to dose and visit schedules
  • ≥ 40 kg
  • surface antigen (HBsAg) positive for at least 6 months
  • Anti-HBs negative
  • Female participants of must agree to use an acceptable

method of from at least 2 weeks prior to Day 1 and continue until at least 1 month after last dose of study drug

Inclusion Criteria for HBeAg(+) participants:

  • HBeAg(+)
  • Anti-HBe(-)

Inclusion Criteria for HBeAg(-) participants:

  • HBeAg(-)
  • Anti-HBe(+)

Exclusion Criteria:

  • Co-infection with the (HIV) or or hepatitis D virus
  • Prior treatment with interferon for hepatitis B
  • Use of nucleoside/nucleotide analogues within 6 months of the screening visit or at any time during the study
  • Use of any drug within 30 days of the screening visit
  • Prior treatment with herbal remedies with known hepatotoxicity. All herbal remedies used for hepatitis B treatment must be discontinued before Day 1
  • Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy
  • Diabetic and/or hypertensive with ocular examination findings
  • History of stroke or
  • Immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], celiac disease, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, hemolytic anemia, scleroderma, sarcoidosis, severe psoriasis requiring oral or injected treatment, or symptomatic thyroid disorder)
  • Chronic pulmonary disease (e.g., , interstitial lung disease, pulmonary fibrosis, sarcoidosis)
  • Current or history of any clinically significant cardiac abnormalities/dysfunction
  • Any medical condition requiring, or likely to require, chronic systemic administration of during the course of the trial
  • Myelodysplastic syndromes
  • Organ transplants (including hematopoietic stem cell transplants) other than cornea and hair
  • Pregnant or nursing, or intending to become pregnant during the trial period
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
402 participants (actual)

Study arms

  • Experimental
    HBeAg(+) PEG-Intron

    HBeAg-positive participants receive 1.5 mcg/kg/wk PEG-Intron subcutaneously (SC) once weekly for 48 weeks.

    Biological: PEG-Intron™

  • Active comparator
    HBeAg(+) PEGASYS

    HBeAg-positive participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.

    Biological: PEGASYS™

  • Experimental
    HBeAg(-) PEG-Intron

    HBeAg-negative participants receive 1.5 mcg/kg/wk PEG-Intron SC once weekly for 48 weeks.

    Biological: PEG-Intron™

  • Active comparator
    HBeAG(-) PEGASYS

    HBeAg-negative participants receive 180 mcg/kg/wk PEGASYS SC once weekly for 48 weeks.

    Biological: PEGASYS™

Interventions

  • BiologicalPEG-Intron™

    PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks

    Also known as: SCH 054031, Pegylated interferon alfa-2b

  • BiologicalPEGASYS™

    PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks

    Also known as: Pegylated interferon alfa-2a

06

What researchers measure

Primary outcomes

  1. Percentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment

    Blood samples were drawn to assess the participant's seroconversion status at Follow-up (FU) Week 24. HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg.

    Time frame: FU Week 24 (Study Week 72)

  2. Percentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment

    The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(-) participants. The percentage of HBeAg(-) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.

    Time frame: FU Week 24 (Study Week 72)

Secondary outcomes

  1. Percentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment

    The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(+)participants. The percentage of HBeAg(+) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.

    Time frame: FU Week 24 (Study Week 72)

  2. Percentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment

    ALT normalization is a desired goal of HBV treatment, which is defined as having abnormal ALT levels at baseline and subsequently normal ALT levels after receiving treatment, where normal is defined as ≤ 1x the upper limit of normal (ULN). The percentage of HBeAg(+) and HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment was reported.

    Time frame: FU Week 24 (Study Week 72)

  3. Percentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment

    HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg. HBV DNA levels in blood were measured by the Roche COBAS TaqMan HBV-(High Pure System Assay). The percentage of HBeAg(+) participants with the combined response of achieving both HBeAg conversion and HBV DNA levels \<2000 IU/mL at 24 weeks post-treatment was reported.

    Time frame: FU Week 24 (Study Week 72)

07

Results

Posted Jan 12, 2017

Participant flow

Hepatitis B envelope antigen (HBeAg)-positive or -negative participants who were interferon treatment-naïve were recruited from 81 sites to be randomly assigned to receive pegylated inferferon alfa-2b (PEG-Intron™) or pegylated interferon alfa-2a (PEGASYS™).

Participant flow — Overall Study
MilestoneHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYS
Started1431455757
Treated (all participants as treated)1421445657
Completed1151304653
Not completed2815114
Withdrew: Adverse event5231
Withdrew: Lost to follow-up2210
Withdrew: Physician decision6501
Withdrew: Protocol violation1001
Withdrew: Withdrawal by subject13561
Withdrew: Not treated1110

Outcome measures

PrimaryPercentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment

Blood samples were drawn to assess the participant's seroconversion status at Follow-up (FU) Week 24. HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg.

Time frame:
FU Week 24 (Study Week 72)
Reported as:
Number · percentage of participants
Percentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment
percentage of participantsHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYS
Percentage of HBeAg(+) Participants Achieving HBeAg Seroconversion at 24 Weeks Post-treatment25.423.6——
Statistical analysis
  • HBeAg(+) PEG-Intron vs HBeAg(+) PEGASYS · Adjusted treatment difference: 1.6 · 95% CI -8.4 to 11.6
PrimaryPercentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment

The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(-) participants. The percentage of HBeAg(-) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.

Time frame:
FU Week 24 (Study Week 72)
Reported as:
Number · percentage of participants
Percentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment
percentage of participantsHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYS
Percentage of HBeAg(-) Participants Achieving Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels <2000 IU/mL at 24 Weeks Post-treatment——30.433.3
Statistical analysis
  • HBeAg(-) PEG-Intron vs HBeAg(-) PEGASYS · Adjusted treatment difference: -3.0 · 95% CI -20.2 to 14.3
SecondaryPercentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment

The Roche COBAS TaqMan HBV-(High Pure System Assay) was used to measure HBV DNA in blood samples of HBeAg(+)participants. The percentage of HBeAg(+) participants with HBV DNA \<2000 IU/mL at 24 weeks post-treatment was reported.

Time frame:
FU Week 24 (Study Week 72)
Reported as:
Number · percentage of participants
Percentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment
percentage of participantsHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYS
Percentage of HBeAg(+) Participants Achieving HBV DNA <2000 IU/mL at 24 Weeks Post-treatment23.921.5——
Statistical analysis
  • HBeAg(+) PEG-Intron vs HBeAg(+) PEGASYS · Adjusted treatment difference: 2.6 · 95% CI -7.2 to 12.3
SecondaryPercentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment

ALT normalization is a desired goal of HBV treatment, which is defined as having abnormal ALT levels at baseline and subsequently normal ALT levels after receiving treatment, where normal is defined as ≤ 1x the upper limit of normal (ULN). The percentage of HBeAg(+) and HBeAg(-) participants achieving ALT normalization at 24 weeks post-treatment was reported.

Time frame:
FU Week 24 (Study Week 72)
Reported as:
Number · percentage of participants
Percentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment
percentage of participantsHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYS
Percentage of HBeAg(+) and HBeAg(-) Participants Achieving Alanine Aminotransferase (ALT) Normalization at 24 Weeks Post-treatment49.347.271.461.4
Statistical analysis
  • HBeAg(+) PEG-Intron vs HBeAg(+) PEGASYS · Adjusted treatment difference: 2.1 · 95% CI -9.5 to 13.6
  • HBeAg(-) PEG-Intron vs HBeAg(-) PEGASYS · Adjusted treatment difference: 10.1 · 95% CI -7.2 to 27.1
SecondaryPercentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment

HBeAg seroconversion was defined as loss of HBeAg in HBeAg(+) participants and development of antibody to HBeAg. HBV DNA levels in blood were measured by the Roche COBAS TaqMan HBV-(High Pure System Assay). The percentage of HBeAg(+) participants with the combined response of achieving both HBeAg conversion and HBV DNA levels \<2000 IU/mL at 24 weeks post-treatment was reported.

Time frame:
FU Week 24 (Study Week 72)
Reported as:
Number · percentage of participants
Percentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment
percentage of participantsHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYS
Percentage of HBeAg(+) Participants Achieving the Combined Response of HBeAg Seroconversion and HBV DNA <2000 IU/mL at 24 Weeks Post-treatment14.813.9——
Statistical analysis
  • HBeAg(+) PEG-Intron vs HBeAg(+) PEGASYS · Adjusted treatment difference: 0.9 · 95% CI -7.4 to 9.2

Adverse events

Collected over SAEs up to 30 days after Week 24 Post-Treatment Visit (up to 76 weeks) Nonserious AEs up to Treatment Week 48 (up to 48 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HBeAg(+) PEG-Intron—12/142 (8.5%)126/142 (88.7%)
HBeAg(+) PEGASYS—10/144 (6.9%)124/144 (86.1%)
HBeAg(-) PEG-Intron—1/56 (1.8%)50/56 (89.3%)
HBeAG(-) PEGASYS—2/57 (3.5%)50/57 (87.7%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAG(-) PEGASYS
MenorrhagiaReproductive system and breast disorders0/1420/1441/560/57
Gallbladder polypHepatobiliary disorders0/1420/1440/561/57
HepatitisHepatobiliary disorders1/1421/1440/561/57
DyspepsiaGastrointestinal disorders0/1422/1440/560/57
Alanine aminotransferase increasedInvestigations0/1422/1440/560/57
Basedow's diseaseEndocrine disorders1/1420/1440/560/57
Retinal vein occlusionEye disorders1/1420/1440/560/57
Duodenal perforationGastrointestinal disorders1/1420/1440/560/57
AstheniaGeneral disorders1/1420/1440/560/57
PyrexiaGeneral disorders1/1420/1440/560/57
Most frequent other events
Showing 10 of 39
Most frequent other events
EventHBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAG(-) PEGASYS
PyrexiaGeneral disorders66/14255/14421/5620/57
AlopeciaSkin and subcutaneous tissue disorders57/14254/14418/5614/57
MyalgiaMusculoskeletal and connective tissue disorders43/14235/14421/5613/57
HeadacheNervous system disorders48/14235/14416/5614/57
FatigueGeneral disorders37/14230/14410/569/57
Influenza like illnessGeneral disorders17/14219/1446/5611/57
Weight decreasedInvestigations9/14216/1449/564/57
Decreased appetiteMetabolism and nutrition disorders17/14221/1445/566/57
PruritusSkin and subcutaneous tissue disorders9/14214/1447/566/57
Injection site reactionGeneral disorders9/1422/1446/560/57

Baseline characteristics

All Participants as Treated (APaT: all randomized participants who received ≥1 dose of study medication

Age, Continuous
Age, Continuous(years)HBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYSTotal
Mean32.6 ± 7.7333.6 ± 9.2341.1 ± 10.7742.0 ± 10.5035.5 ± 9.91
Sex: Female, Male
Sex: Female, Male(Participants)HBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYSTotal
Female54432115133
Male881013542266
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)HBeAg(+) PEG-IntronHBeAg(+) PEGASYSHBeAg(-) PEG-IntronHBeAg(-) PEGASYSTotal
Asian1421445657399
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Jan 2016, 37 months.

Results were first posted in Jan 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2012
First posted
Jul 17, 2012
StartActual
Nov 26, 2012
Primary completionActual
Jan 21, 2016
CompletionActual
Jan 21, 2016
Results first posted
Jan 12, 2017
Last update
Aug 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01641926
Responsible party
Sponsor
First posted
Jul 17, 2012
Start date
Nov 26, 2012
Primary completion
Jan 21, 2016
Completion
Jan 21, 2016
Results posted
Jan 12, 2017
Last update
Aug 27, 2018

Study contacts

Study Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion